Edition:
United States

Supernus Pharmaceuticals Inc (SUPN.O)

SUPN.O on Consolidated Issue listed on NASDAQ Global Market

23.45USD
20 Jan 2017
Change (% chg)

$-0.05 (-0.21%)
Prev Close
$23.50
Open
$23.55
Day's High
$23.80
Day's Low
$23.10
Volume
340,824
Avg. Vol
635,306
52-wk High
$27.50
52-wk Low
$9.51

SUPN.O

Chart for SUPN.O

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $1,163.45
Shares Outstanding(Mil.): 49.51
Dividend: --
Yield (%): --

Financials

  SUPN.O Industry Sector
P/E (TTM): 46.07 29.62 30.50
EPS (TTM): 0.51 -- --
ROI: 19.27 15.43 14.85
ROE: 21.45 16.61 16.27

BRIEF-Supernus provides business update

* Supernus Pharmaceuticals Inc - net product sales for Q3 of 2016 were $55.6 million, a 44.1% increase over $38.6 million in same period last year

Nov 14 2016

BRIEF-Supernus Pharmaceuticals sees 2016 net product sales in range of $205 mln to $210 mln

* Sees 2016 net product sales in range of $205 million to $210 million

Nov 14 2016

BRIEF-Supernus Pharmaceuticals files for non-timely 10-Q

* Additional time needed to solve issue concerning accounting treatment of $30 million royalty monetization deal recorded as revenue in July 2014

Nov 10 2016

BRIEF-Supernus Pharmaceuticals reports positive results from Phase IIB clinical trial for SPN-812

* Supernus announces positive results from Phase IIB clinical trial for SPN-812 in children with ADHD

Oct 11 2016

BRIEF-Supernus Pharma receives FDA tentative approval for expanded label of Trokendi XR

* Supernus receives FDA tentative approval for expanded label of Trokendi XR to include migraine prophylaxis in adults

Aug 19 2016

BRIEF-Supernus Pharma says Charles W Newhall III elected chairman

* Supernus announces resignation of Dr. James Barrett from board of directors; Charles W. Newhall, III elected chairman Source text for Eikon: Further company coverage:

Aug 12 2016

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $40.46 +0.06
AstraZeneca plc (AZN.L) 4,318.50 -150.00
Eli Lilly and Co (LLY.N) $76.81 -0.03
Shire PLC (SHP.L) 4,393.00 -90.50
Shire PLC (3159084.L) -- --
Smiths Group plc (SMIN.L) 1,490.00 -2.00

Earnings vs. Estimates